Catalyst Pharmaceuticals (CPRX) Non Operating Income (2014 - 2026)
Catalyst Pharmaceuticals posted quarterly Non Operating Income of $11.0 million for Q1 2026, up 38.87% year-on-year from $7.9 million in Q1 2025, and up 9.37% on a QoQ basis from $10.1 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 13 years of Non Operating Income data on file, last reported at $11.0 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 38.87% year-over-year to $11.0 million; the trailing twelve-month figure through Mar 2026 stood at $28.8 million (up 6.35% YoY), and the FY2025 full-year result was $25.7 million, up 21.75% from the prior year.
- Non Operating Income for Q1 2026 stood at $11.0 million, up from $10.1 million in the prior quarter.
- Across five years, Non Operating Income topped out at $11.3 million in Q4 2024 and bottomed at -$833000.0 in Q3 2023.
- The 5-year median for Non Operating Income is $2.2 million (2022), against an average of $4.0 million.
- Peak annual rise in Non Operating Income reached 3008.45% in 2022, while the deepest fall reached 622.58% in 2022.
- A 5-year view of Non Operating Income shows it stood at $2.2 million in 2022, then surged by 127.23% to $5.0 million in 2023, then surged by 126.08% to $11.3 million in 2024, then decreased by 11.32% to $10.1 million in 2025, then climbed by 9.37% to $11.0 million in 2026.
- The last three Non Operating Income figures came in at $11.0 million (Q1 2026), $10.1 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 11.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.00 Mn |
| Dec 31, 2025 | 10.06 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Mar 31, 2025 | 7.92 Mn |
| Dec 31, 2024 | 11.34 Mn |
| Sep 30, 2024 | 6.30 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Mar 31, 2024 | 1.96 Mn |
| Dec 31, 2023 | 5.02 Mn |
| Sep 30, 2023 | -833,000.00 |
| Jun 30, 2023 | 1.81 Mn |
| Mar 31, 2023 | 1.70 Mn |
| Dec 31, 2022 | 2.21 Mn |
| Sep 30, 2022 | 905,000.00 |
| Jun 30, 2022 | -324,000.00 |
| Mar 31, 2022 | 93,000.00 |
| Dec 31, 2021 | 71,000.00 |
| Sep 30, 2021 | 68,000.00 |
| Jun 30, 2021 | 62,000.00 |
| Mar 31, 2021 | 81,000.00 |
| Dec 31, 2020 | 106,000.00 |
| Sep 30, 2020 | 33,000.00 |
| Jun 30, 2020 | 111,000.00 |
| Mar 31, 2020 | 336,000.00 |
| Dec 31, 2019 | 398,909.00 |
| Sep 30, 2019 | 393,415.00 |
| Jun 30, 2019 | 450,410.00 |
| Mar 31, 2019 | 343,266.00 |
| Dec 31, 2018 | 343,658.00 |
| Sep 30, 2018 | 343,730.00 |
| Jun 30, 2018 | 370,715.00 |
| Mar 31, 2018 | 233,548.00 |
| Dec 31, 2017 | 124,088.00 |
| Sep 30, 2017 | 129,059.00 |
| Jun 30, 2017 | 91,039.00 |
| Mar 31, 2017 | 109,977.00 |
| Dec 31, 2016 | 43,933.00 |
| Sep 30, 2016 | 66,981.00 |
| Jun 30, 2016 | 92,755.00 |
| Mar 31, 2016 | 117,943.00 |
| Dec 31, 2015 | -13,075.00 |
| Sep 30, 2015 | 46,659.00 |
| Jun 30, 2015 | 4,871.00 |
| Mar 31, 2015 | 61,934.00 |
| Dec 31, 2014 | 21,805.00 |
| Sep 30, 2014 | 5,924.00 |
| Jun 30, 2014 | 15,744.00 |
| Mar 31, 2014 | 32,760.00 |